

REMARKS

Interview Summary

The substance of the Interview on February 17, 2004 between Examiner Robinson, Dr. Carney and the undersigned is set forth in the Interview Summary provided to Applicants by Examiner Robinson after the Interview. The Interview Summary is incorporated herein by reference.

Claim Amendments and new Claims 29-44

The subject matter of Claims 1 and 6, as amended, and new Claims 29-44 is fully supported in the present application as filed July 19, 2001. Support can be found in the specification, for example, at 3, lines 3-9; page 5, line 26 to page 8, line 10; page 8, lines 28-29, which incorporates by reference the entire contents of U.S. Patent Nos. 5,500,412 and 5,352,664; in the two paragraphs added at page 6, line 12; at page 9, line 4 to page 10, line 22; page 11, line 26 to page 12, line 13; page 12, line 28 to page 5; and in originally filed Claims 1-21. No new matter has been added by the new claims or by the amendments to Claims 1 and 6.

Specification Amendments

The specification has been amended at various locations to recite the proper notation for the sequence identifiers. No new matter has been added by the amendments to the specification.

Sequence Listing

Transmitted concurrently herewith is a copy of a Substitute "Sequence Listing" in paper form (sheets 1/3 through 3/3) comprising SEQ ID NOs: 1-6 for the above-identified patent application as required by 37 C.F.R. §§ 1.825(a) and 1.821(c), and a copy of the Substitute "Sequence Listing" in computer readable form as required by 37 C.F.R. §§ 1.825(b) and 1.821(e). Please replace the "Sequence Listing" filed on July 19, 2001 (sheets 1/2 through 2/2) with the Substitute "Sequence Listing" filed concurrently herewith.

The Substitute Sequence Listing filed concurrently herewith adds SEQ ID NO: 6 which consists of the 23 amino acid sequence Ala-Gly-Try-Lys-Pro-Asp-Glu-Gly-Lys-Arg-Gly-Asp-

Ala-Cys-Glu-Gly-Asp-Ser-Gly-Gly-Pro-Phe-Val and an amide at the C-terminus. Support for SEQ ID NO: 6 is found in the amended specification, for example, at page 7, lines 15-16, where it is stated that SEQ ID NO: 6 has the identical amino acid sequence of SEQ ID NO: 5 and also contains a C-terminal amide.

As required by 37 C.F.R. § 1.825(b), Applicants' Attorney hereby states that the contents of the Substitute "Sequence Listing" in paper form and in the computer readable form submitted concurrently herewith are the same and, as required by 37 C.F.R. § 1.825(a), also states that the submission includes no new matter.

Terminal Disclaimer


Transmitted concurrently herewith is a Terminal Disclaimer in which the owner of the instant application disclaims, except as provided in the Terminal Disclaimer, the terminal part of the statutory term of any patent granted on the instant application, which would extend beyond the expiration date of the full statutory term of any patent on the pending second Application Number 10/050,688 filed on January 16, 2002.

CONCLUSION

In view of the above amendments and remarks, it is believed that all claims are in condition for allowance, and it is respectfully requested that the application be passed to issue. If the Examiner feels that a telephone conference would expedite prosecution of this case, the Examiner is invited to call the undersigned.

Respectfully submitted,

HAMILTON, BROOK, SMITH & REYNOLDS, P.C.

By 

Steven G. Davis

Registration No. 39,652

Telephone: (978) 341-0036

Facsimile: (978) 341-0136

Concord, MA 01742-9133

Dated: February 20 2004